Update shared on 21 Nov 2025
Fair value Increased 0.017%Analysts have modestly raised their price target for Penumbra from $306.74 to $306.79, citing incremental improvements in projected revenue growth and a slight decrease in the discount rate as key factors supporting the adjustment.
What's in the News
- Penumbra updated its 2025 guidance, increasing expected total revenue to $1.375 to $1.38 billion, reflecting 15% to 16% growth over 2024, and maintained its gross and operating margin outlook for the year (Corporate Guidance).
- Results from the STORM-PE randomized controlled trial showed that use of computer assisted vacuum thrombectomy (CAVT) in combination with anticoagulation led to significantly better outcomes for patients with acute intermediate-high risk pulmonary embolism, including improved thrombus reduction, early physiological recovery, and greater functional improvement compared to anticoagulation alone (Product-Related Announcement).
- Penumbra completed its $100 million share repurchase plan announced in August 2024, having repurchased 517,763 shares, or 1.33% of outstanding shares. No additional shares were repurchased in the most recent tranche (Buyback Tranche Update).
Valuation Changes
- Consensus Analyst Price Target: Increased slightly from $306.74 to $306.79 per share.
- Discount Rate: Decreased marginally from 7.74% to 7.74%.
- Revenue Growth: Projected growth edged up from 13.71% to 13.73%.
- Net Profit Margin: Slipped slightly from 15.09% to 15.01%.
- Future P/E increased from 53.16x to 53.41x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.